Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Citations Over TimeTop 1% of 2020 papers

Abstract

Coronavirus disease 2019 (COVID-19) represents a global crisis, yet major knowledge gaps remain about human immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We analyzed immune responses in 76 COVID-19 patients and 69 healthy individuals from Hong Kong and Atlanta, Georgia, United States. In the peripheral blood mononuclear cells (PBMCs) of COVID-19 patients, we observed reduced expression of human leukocyte antigen class DR (HLA-DR) and proinflammatory cytokines by myeloid cells as well as impaired mammalian target of rapamycin (mTOR) signaling and interferon-α (IFN-α) production by plasmacytoid dendritic cells. By contrast, we detected enhanced plasma levels of inflammatory mediators-including EN-RAGE, TNFSF14, and oncostatin M-which correlated with disease severity and increased bacterial products in plasma. Single-cell transcriptomics revealed a lack of type I IFNs, reduced HLA-DR in the myeloid cells of patients with severe COVID-19, and transient expression of IFN-stimulated genes. This was consistent with bulk PBMC transcriptomics and transient, low IFN-α levels in plasma during infection. These results reveal mechanisms and potential therapeutic targets for COVID-19.

Related Papers

• → Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2(2021)26 cited
• → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited
• The Covid‐19 Pandemic Highlights Key Roles for Economists La pandémie de Covid‐19 met en évidence les rôles importants des économistes Die Covid‐19‐Pandemie unterstreicht die Schlüsselrolle von Ökonominnen und Ökonomen(2020)
• → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)
• → Спонтанний пневмоторакс у хворих на нову коронавірусну хворобу SARS-CoV-2 COVID-19(2022)